More Samsung Bioepis biosimilar data published that outshines original

29 January 2018

Korean biosimilar company Samsung Bioepis is making a habit of presenting data on its products that shows that they not only compare with the original, but could actually be superior to the reference drug.

Last week the company, which is a joint venture between the Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB), had a research note accepted for publication in the British Journal of Dermatology, suggests the firm’s etanercept biosimilar may be less immunogenic than the reference product Enbrel, produced by Amgen (Nasdaq: AMGN).

Now Samsung Bioepis has had some strong Phase III study data published in the Journal of Clinical Oncology on its SB3 product, a copy of Roche’s (ROG: SIX) breast cancer drug Herceptin (trastuzumab).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK